|
1. BIOLOGIE
|
|
|
|
|
|
1.1 BIOLOGIE - GÉNOME
|
|
|
Out of Many Ovarian Precancerous Lesions, One Becomes Cancer [Johns Hopkins]
|
|
|
|
|
|
In a novel study of cancer genetics using fallopian tube tissue from 15 women, researchers at the Johns Hopkins Kimmel Cancer Center say they have found evidence that the most common and lethal type of ovarian cancer arises not from a uniform group of precancerous lesions, but from individual growths found in groups genetically unrelated to each other.
|
|
|
|
|
|
|
2.7 ETIOLOGIE - OBÉSITÉ
|
|
|
|
4.15 DÉP., DIAG. & PRONO. - IMAGERIE
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
5. TRAITEMENTS
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
These Protein Picker-Uppers Keep Your Cells Clean and Healthy [Wired]
|
|
|
|
|
|
Whereas small molecules like ibuprofen and benadryl gum up proteins, and Crispr knocks out the genes that make proteins, protein degraders offer a radical new way to selectively reach into cells and attack a whole host of historically difficult-to-treat diseases caused by misbehaving molecules, from Alzheimer’s to Parkinson’s to many types of cancer.
|
|
|
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
Celgene dips out of deals ahead of mega-merger [Biopharma Dive]
|
|
|
|
|
|
The mega-merger between Bristol-Myers and Celgene may affect dozens of biotechs that partner with the companies. But even early on, BeiGene's deal looked particularly vulnerable to change because it centered around immuno-oncology — an area Bristol-Myers has well-covered with its blockbuster PD-1 drug Opdivo (nivolumab).
|
|
|
|
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
5.12.4 IMMUNOTHÉRAPIES - ESSAIS
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
Colorectal Cancer Data Spurs Pfizer to Pay $11.4B for Array Bio [Xconomy]
|
|
|
|
|
|
Pfizer’s chief scientific officer added that Array has the capability to bring one new drug candidate to human testing each year for the foreseeable future, “possibly starting in 2019,” he said. Primarily, however, Pfizer’s acquisition of Array is a bet on the future of the Braftovi-Mektovi combo.
|
|
|
|
|
|
|
|
|
Pfizer to Acquire Array BioPharma [Pfizer]
|
|
|
|
|
|
Opportunity to strengthen category leadership in Oncology with the addition of a breakthrough combination of BRAF/MEK inhibitors under investigation for a potential first-in-class therapy for patients with BRAF-mutant metastatic colorectal cancer.
|
|
|
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia [NCI]
|
|
|
|
|
|
The combination therapy used as a comparison in the trial—obinutuzumab plus chlorambucil—is approved for patients with untreated CLL, but the treatment is rarely used, according to Dr. Miljković. “A more relevant comparison in the trial would have been between the venetoclax–obinutuzumab combination and ibrutinib,” Dr. Miljković said.
|
|
|
|
|
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|